Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sino Biopharmaceutical ( (HK:1177) ) just unveiled an update.
Sino Biopharmaceutical Limited has announced that its innovative drug, LM-302 ‘CLDN18.2 ADC’, developed by its subsidiary LaNova Medicines, has been included in China’s Breakthrough Therapeutic Designation process. This drug, used in combination with a PD-1 monoclonal antibody, shows promise as a first-line therapy for certain advanced cancers. Recent clinical trials have demonstrated significant efficacy and manageable safety, with high response and disease control rates. The inclusion in the BTD process is expected to expedite the drug’s market availability, offering a new treatment option for patients with CLDN18.2-positive gastric cancer.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited operates in the pharmaceutical industry, focusing on the development and production of innovative drugs. The company, through its subsidiary LaNova Medicines Limited, specializes in antibody-drug conjugates and targets diseases such as gastric, pancreatic, and biliary tract cancers.
Average Trading Volume: 176,746,548
Technical Sentiment Signal: Buy
Current Market Cap: HK$139.9B
Find detailed analytics on 1177 stock on TipRanks’ Stock Analysis page.